Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: An Italian cohort study

Journal of Evaluation in Clinical Practice

Volumn 10, Issue 4, 2004, Pages 511-518

  Russo, Pierluigi ^a   Paolillo, Andrea ^b   Caprino, Luciano ^a   Bastianello, Stefano ^c   Bramanti, Placido ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c European Biomedical Foundation   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cohort study; Interferon beta; Propensity score; Relapsing remitting multiple sclerosis; Treatment effectiveness

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE;

ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEPRESSION; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POISSON DISTRIBUTION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; COHORT STUDIES; CROSS-OVER STUDIES; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INTERFERON-BETA; ITALY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OBSERVATION; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 7944224160     PISSN: 13561294     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2003.00436.x     Document Type: Article

References (32)

1. Beck R.W., Chandler D.L., Cole S.R. et al. (2002) Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Annals of Neurology 51, 481-490.
2. Benson K. & Hartz A.J. (2000) A comparison of observational studies and randomized controlled trials. New England Journal of Medicine 342, 1878-1886.
3. Brex P.A., Gomez Anson B., Parker G.J. et al. (1999) Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. Journal of the Neurological Sciences 166, 16-22.
4. Chofflon M. (2000) Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials. European Journal of Neurology 7, 369-380.
5. Comi G., Filippi M., Barkhof F. et al. & The Early Treatment of Multiple Sclerosis Study Group (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357, 1576-1582.
6. Concato J., Shah N. & Horwitz R.I. (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. New England Journal of Medicine 342, 1887-1892.
7. D'Agostino R.B. (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statististics in Medicine 17, 2265-2281.
8. Goodin D.S., Frohman E.M., Garmany G.P. et al. (2002) Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58, 169-178.
9. Grizzle A. & Armstrong E.P. (2001) The role and use of outcome assessments. In Introduction to Applied Pharmacoeconomics (ed. F.R. Vogenberg), pp. 40-60. McGraw-Hill, New York.
10. Gum P.A., Thamilarasan M., Watanabe J. et al. (2001) Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. Journal of American Medical Association 286, 1187-1194.
11. Jacobs L.D., Beck R.W., Simon J.H. et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine 343, 898-904.
12. Johnson K.P., Brooks B.R., Cohen J.A. et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of the phase III multicenter, double-blind, placebo-controlled trial. Neurology 45, 1268-1276.
13. Johnson K.P., Brooks B.R., Ford C.C. et al. & the Copolymer 1 Multiple Sclerosis Study Group (2000) Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis 6, 255-266.
14. Kurtzke J.F. (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444-1452.
15. Liu C. & Blumhardt L.D. (2000a) Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. Journal of Neurology Neurosurgery and Psychiatry 68, 450-457.
16. Liu C. & Blumhardt L.D. for the Copolymer 1 Multiple Sclerosis Study Group (2000b) Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. Journal of the Neurological Sciences 181, 33-37.
17. Liu C. & Blumhardt L.D. (2002) Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: a categorical disability trend analysis. Multiple Sclerosis 8, 10-14.
18. Matthews J.N.S., Altman D.G., Campbell M.J. & Royston P. (1990) Analysis of serial measurements in medical research. British Medical Journal 300, 230-235.
19. Murphy N. et al. & the Cost of Multiple Sclerosis Study Group (1998) Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 13, 607-622.
20. Noseworthy J.H., Lucchinetti C., Rodriguez M. & Weinshenker B.G. (2000) Multiple sclerosis. New England Journal of Medicine 343, 939-952.
21. Pocock S.J. & Elbourne D.R. (2000) Randomized trials or observational tribulations? New England Journal of Medicine 342, 1907-1909.
22. Polman C.H. & Uitdehaag B.M.J. (2000) Drug treatment of multiple sclerosis. British Medical Journal 321, 490-494.
23. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis)-2 Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352, 1498-1504.
24. PRISMS-4 Study Group (2001) Long-term efficacy of interferon beta-1a in relapsing MS. Neurology 56, 1628-1636.
25. Rich M.W. (2002) From clinical trials to clinical practice. Journal of American Medical Association 287, 1321-1323.
26. Roland M. & Torgerson D.J. (1998) Understanding controlled trials: what are pragmatic trials? British Medical Journal 316, 285.
27. Rosenbaum P.R. & Rubin D.B. (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70, 41-55.
28. Rubin D.B. (1997) Estimating causal effects from large data sets using propensity scores. Annals of Internal Medicine 127, 757-763.
29. Rudick R.A., Cohen J.A., Weinstock-Guttman B. et al. (1997) Management of multiple sclerosis. New England Journal of Medicine 337, 1604-1611.
30. Stenestrand U. & Wallentin L. for the Swedish Register of Cardiac Intensive Care (RIKS-HIA) (2001) Early statin treatment following acute myocardial infarction and 1-year survival. Journal of American Medical Association 285, 430-436.
31. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 43, 655-661.
32. The IFNB Multiple Sclerosis Study Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45, 1277-1285.